Research Paper Volume 16, Issue 18 pp 12623—12650
Exploring the therapeutic mechanism of Yuebi decoction on nephrotic syndrome based on network pharmacology and experimental study
Figure 9. Molecular docking of representative ingredients and targets (the affinity energy is less than or equal to −7.0 kcal/mol). (A) Quercetin acts on TRPC6. (B) Kaempferol acts on TRPC6. (C) Luteolin acts on TRPC6. (D) Naringenin acts on TRPC6. (E) Quercetin acts on STAT3. (F) Kaempferol acts on STAT3. (G) Luteolin acts on STAT3. (H) Naringenin acts on STAT3. (I) Quercetin acts on PPP3CA. (J) Kaempferol acts on PPP3CA. (K) Luteolin acts on PPP3CA. (L) Naringenin acts on PPP3CA. (M) Beta-sitosterol acts on PPP3CA. (N) Quercetin acts on NFATC3. (O) Kaempferol acts on NFATC3. (P) Luteolin acts on NFATC3. The molecule was represented in a ball-stick model with atoms C and O in green and red, respectively.